

REMARKS

By amendment above, new claims 44-52 have been added. Support for these claims can be found in original claims 14-22, respectively. No new matter is introduced into the application by way of these amendments.

In the outstanding Office Action, the examiner set forth a restriction requirement in which the claims were said to be directed to four inventions as follows:

Group I: claims 1-24, drawn to oligonucleotides and vectors;

Group II: claims 25-41, drawn to methods of preparing oligonucleotides and gene mapping

Group III: claim 42, drawn to methods of recovering full-length cDNA; and

Group IV: claim 43, drawn to methods for quantifying transcriptional activity of a gene.

The examiner further asserted that claims of the application were directed to patentably distinct species:

a) restriction enzymes recited in claim 9 of Group I; and

b) restriction enzymes recited in claim 35 of Group II.

Applicants hereby elect the claims of Group II, claims 25-41, for initial prosecution on the merits. Applicants request that new claims 44-52 be included in Group II. Each of the new claims depends, directly or indirectly from an elected claim. With regard to the requested election of species, Applicants hereby elect restriction enzyme Mmel.

Applicants respectfully submit that the claims are in condition for allowance.

Respectfully submitted,

By Barbara G. Ernst
Barbara G. Ernst
Attorney for Applicants
Registration No. 30,377
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040